drugset / Trial / NCT05020249

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque Psoriasis

NCT05020249

Phase 3 Completed 47 enrolled UCB Biopharma SRL
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of the study is to evaluate the efficacy and safety of bimekizumab compared with placebo.

Timeline

Start
2021-09-27
Primary completion
2022-09-05
Completion
2022-09-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Bimekizumab Monoclonal antibody Subcutaneous

Indications